Facilitating Innovation to Fight Coronavirus Act This bill provides immunity from civil liability to health care providers for certain actions taken during the COVID-19 (i.e., coronavirus disease 2019) public health emergency and lengthens the terms of certain medical patents related to the treatment of COVID-19. Specifically, when testing for or treating COVID-19 during the public health emergency, a health care provider may not be held liable in any federal, state, or local civil proceeding for (1) using or modifying a medical device for an unapproved use or indication; (2) practicing without a license or outside of an area of specialty, if instructed to do so by an individual with such a license or within such an area of speciality; or (3) conducting the testing of, or providing treatment to, a patient outside of the premises of standard health care facilities. Additionally, certain medical patents that are issued with respect to the treatment of COVID-19 are deemed not to begin until the termination of the presidential emergency declaration relating to COVID-19 and are extended for an additional 10 years.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Read twice and referred to the Committee on the Judiciary.
Law
Cardiovascular and respiratory healthCivil actions and liabilityDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careHealth personnelHealth technology, devices, suppliesInfectious and parasitic diseasesIntellectual propertyLicensing and registrationsManufacturingMedical tests and diagnostic methodsProduct safety and quality
Facilitating Innovation to Fight Coronavirus Act
USA116th CongressS-3630| Senate
| Updated: 5/6/2020
Facilitating Innovation to Fight Coronavirus Act This bill provides immunity from civil liability to health care providers for certain actions taken during the COVID-19 (i.e., coronavirus disease 2019) public health emergency and lengthens the terms of certain medical patents related to the treatment of COVID-19. Specifically, when testing for or treating COVID-19 during the public health emergency, a health care provider may not be held liable in any federal, state, or local civil proceeding for (1) using or modifying a medical device for an unapproved use or indication; (2) practicing without a license or outside of an area of specialty, if instructed to do so by an individual with such a license or within such an area of speciality; or (3) conducting the testing of, or providing treatment to, a patient outside of the premises of standard health care facilities. Additionally, certain medical patents that are issued with respect to the treatment of COVID-19 are deemed not to begin until the termination of the presidential emergency declaration relating to COVID-19 and are extended for an additional 10 years.
Cardiovascular and respiratory healthCivil actions and liabilityDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careHealth personnelHealth technology, devices, suppliesInfectious and parasitic diseasesIntellectual propertyLicensing and registrationsManufacturingMedical tests and diagnostic methodsProduct safety and quality